Recent Updates on Diabetes and Bone
Open Access
- 22 August 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8140
Abstract
Diabetes represents one of the major challenges in preserving health in the 21st century. It has been estimated that in 2050, 853 million subjects will live with diabetes. It was also reported that 3.4 million adults died from diabetes and related comorbidities. Chronic hyperglycemia, if not properly managed, leads to skeletal fragility with fracture risk that augments with age. In type 1 diabetes (T1D), the augmented fracture risk can be partially explained by lower areal bone mineral density (aBMD). Interestingly, in type 2 diabetes (T2D), the risk of fractures increases with normal or elevated aBMD. In this review, the recent updates on diabetes and bone health (2023–2025) are reported, thus describing bone quality and the role of mediators involved in diabetes pathogenesis. Consequently, the role of Vitamin D, Incretins, Glucagon-like peptide-2 (GLP-2), neurotensin, asprosin, irisin, and Thioredoxin-interacting protein (TXNIP) will be described considering the interplay between diabetes and bone health. The importance of monitoring diabetic patients’ bone health is underlined, together with the therapeutic approaches to avoid fractures.Keywords
This publication has 71 references indexed in Scilit:
- Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitusOsteoporosis International, 2025
- Diabetes and Bone Health: A Comprehensive Review of Impacts and MechanismsDiabetes/Metabolism Research and Reviews, 2025
- Bone microstructure and TBS in diabetes: what have we learned? A narrative reviewOsteoporosis International, 2025
- Relationship of Serum 25‐Hydroxyvitamin D Concentrations, Diabetes, Vitamin D Receptor Gene Polymorphisms and Incident Venous ThromboembolismDiabetes/Metabolism Research and Reviews, 2024
- Circulating Proneurotensin Levels Predict Impaired Bone Mineralisation in Postmenopausal Women With Type 2 Diabetes MellitusDiabetes/Metabolism Research and Reviews, 2024
- Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal StudyCalcified Tissue International, 2024
- Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplayDiabetologia, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic ReviewJBMR Plus, 2023
- The association between prediabetes and bone mineral density: A meta‐analysisDiabetes/Metabolism Research and Reviews, 2023